LEADER 01590nam0-2200469---450-
001 990001179200203316
005 20130225130643.0
010   $a88-02-05356-1
035   $a000117920
035   $aUSA01000117920
035   $a(ALEPH)000117920USA01
035   $a000117920
100   $a20030925d1998----km-y0enga50------ba
101 0 $aita
102   $aIT
105   $aa|||z|||001yy
200 1 $a<<L'>> erbario delle quattro stagioni$fBasilius Besler$gintroduzione e descrizione delle piante a cura di Gèrard G. Aymonin Basilius Besler,$gprefazione di Pierre Gascar,$gtraduzione di Maria Teresa Della Beffa.$gGèrard G. Aymonin, Pierre Gascar, Maria Teresa Della Beffa
210   $aTorino$cUTET$dcopyr. 1998
210   $aMilano$cGarzanti$dcopyr. 1998
215   $a538 p.$cill.$d39 cm
300   $aIn custodia
410  0$12001
454   $1<<L'>> herbier des quatre saisons
461  1$1001-------$12001
606 0 $aErbari
676   $a580.74
700  1$aBESLER,$bBasilius$0476010
702  1$aAYMONIN,$bGèrard G.
702  1$aGASCAR,$bPierre
702  1$aDELLA BEFFA,$bMaria Teresa
801  0$aIT$bSalbc$gISBD$cISBD
912   $a990001179200203316
951   $a580.74 BES$b1521 FARM$c580.74
959   $aBK
969   $aFAR
979   $aSIAVPROV$b10$c20030925$lUSA01$h1023
979   $aSIAV1$b10$c20030930$lUSA01$h1116
979   $aSIAV1$b10$c20030930$lUSA01$h1222
979   $aPATRY$b90$c20040406$lUSA01$h1724
979   $aANNASEN$b90$c20130225$lUSA01$h1306
996   $aErbario delle quattro stagioni$9242749
997   $aUNISA

LEADER 01548nam  2200373   450 
001 9910688600803321
005 20230623194921.0
024 7 $a10.5772/intechopen.87599
035   $a(CKB)5400000000042198
035   $a(NjHacI)995400000000042198
035   $a(EXLCZ)995400000000042198
100   $a20230623d2021      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMultiple Myeloma /$fedited by Ota Fuchs
210  1$aLondon, England :$cIntechOpen,$d2021.
215   $a1 online resource (126 pages)
311   $a1-83968-622-7 
330   $aThis book deals with the diagnosis and treatment of multiple myeloma. Multiple myeloma is a plasma cell disorder, the prognosis of which has dramatically improved in the last years thanks to new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, in relapsed/refractory disease and a diagnosis. Chapters cover such topics as prognostic and predictive factors in newly diagnosed multiple myeloma, treatment approaches, antibody therapies, and three-dimensional (3D) models mimicking multiple myeloma bone marrow-microenvironment interactions.
606   $aBones$xCancer
606   $aBones$xTumors
615  0$aBones$xCancer.
615  0$aBones$xTumors.
676   $a616.99471
702   $aFuchs$b Ota
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688600803321
996   $aMultiple Myeloma$91522185
997   $aUNINA